BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
#4PRI RANKED
Most Cited Paper
in Monoclonal and Polyclonal Antibodies Research
18 Months Post-Publication
Class of 2026
“BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026/
Topics
BL-B01D1 · EGFR–HER3 bispecific antibody–drug conjugate · locally advanced solid tumours · Metastatic solid tumors · Phase I trial · Phase I trial · EGFR targeting · HER3 targeting · bispecific antibody · antibody-drug conjugate
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026. Accessed 2026-07-15. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459